國立虎尾科技大學 |

Gene and Cellular Immunotherapy for Cancer

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Gene and Cellular Immunotherapy for Cancer / edited by Armin Ghobadi, John F. DiPersio.
other author:	DiPersio, John F.
Description:	X, 378 p. 29 illus., 28 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Medical Microbiology. -
Online resource:	https://doi.org/10.1007/978-3-030-87849-8
ISBN:	9783030878498

Gene and Cellular Immunotherapy for Cancer
Gene and Cellular Immunotherapy for Cancer [electronic resource] /edited by Armin Ghobadi, John F. DiPersio. - 1st ed. 2022. - X, 378 p. 29 illus., 28 illus. in color.online resource. - Cancer Drug Discovery and Development,2196-9914. - Cancer Drug Discovery and Development,.

The History of Cellular Therapies -- Basics of Immunity -- Biology of CAR T cells -- Cell types used for CAR generation -- Combination therapeutics with CART cell therapy -- Safety switches used for cellular therapies -- Off-the-shelf CAR-T -- Manufacturing of CAR-T Cells: the Assembly Line -- Navigating Regulations in Gene and Cell Immunotherapy -- Bringing CAR-T to the Clinic -- CAR T-Cell Complications -- Mechanisms of Resistance and Relapse after CAR T cell therapy -- Tumor infiltrating lymphocytes (TIL): from bench to bedside -- T-cell Receptor (TCR) Engineered Cells and Their Transition to Clinic -- Viral Cytotoxic T Lymphocytes (CTLs): from Bench to Bedside -- Biology of NK cells and NK cells in clinic -- Biology and Clinical Evaluation of T/NK Cell Engagers -- Roadmap for Starting an Outpatient Cellular Therapy Program -- Index.

Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL). These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including CAR-T, TCR-T, TIL, Viral CTLs, NK cells in addition to T/NK cell engagers, focusing on their historical perspectives, biology, development and manufacturing, toxicities and more. Edited by two leading experts on gene and cellular immunotherapy, the book will feature chapters written by a diverse collection of recognized and up-and-coming experts and researchers in the field, providing oncologists, immunologists, researchers and clinical and basic science trainees with a bench to bedside view of the latest developments in the field.

ISBN: 9783030878498

Standard No.: 10.1007/978-3-030-87849-8doiSubjects--Topical Terms:

668401
Medical Microbiology.

LC Class. No.: R850.A1-854

Dewey Class. No.: 610.72

Gene and Cellular Immunotherapy for Cancer
LDR:03518nam a22004215i 4500 001 1091976
003 DE-He213
005 20220117114730.0
007 cr nn 008mamaa
008 221228s2022 sz | s |||| 0|eng d
020 $a 9783030878498 $9 978-3-030-87849-8
024 7 $a 10.1007/978-3-030-87849-8 $2 doi
035 $a 978-3-030-87849-8
050 4 $a R850.A1-854
050 4 $a QH315-320
072 7 $a MBGR $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MBGR $2 thema
082 0 4 $a 610.72 $2 23
245 1 0 $a Gene and Cellular Immunotherapy for Cancer $h [electronic resource] / $c edited by Armin Ghobadi, John F. DiPersio.
250 $a 1st ed. 2022.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Humana, $c 2022.
300 $a X, 378 p. 29 illus., 28 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Cancer Drug Discovery and Development, $x 2196-9914
505 0 $a The History of Cellular Therapies -- Basics of Immunity -- Biology of CAR T cells -- Cell types used for CAR generation -- Combination therapeutics with CART cell therapy -- Safety switches used for cellular therapies -- Off-the-shelf CAR-T -- Manufacturing of CAR-T Cells: the Assembly Line -- Navigating Regulations in Gene and Cell Immunotherapy -- Bringing CAR-T to the Clinic -- CAR T-Cell Complications -- Mechanisms of Resistance and Relapse after CAR T cell therapy -- Tumor infiltrating lymphocytes (TIL): from bench to bedside -- T-cell Receptor (TCR) Engineered Cells and Their Transition to Clinic -- Viral Cytotoxic T Lymphocytes (CTLs): from Bench to Bedside -- Biology of NK cells and NK cells in clinic -- Biology and Clinical Evaluation of T/NK Cell Engagers -- Roadmap for Starting an Outpatient Cellular Therapy Program -- Index.
520 $a Clinical and preclinical exploration of gene and cellular immunotherapy have seen rapid growth and interest with the development and approval of five Chimeric Antigen Receptor T-cell (CAR-T) products for lymphoma and myeloma and one Bispecific T-Cell Engager (BiTE) for acute lymphoblastic leukemia (ALL). These advances have dramatically improved the management of patients with relapsed refractory lymphoma, myeloma and leukemia. Gene and Cellular Immunotherapy for Cancer offers readers a comprehensive review of current cellular and gene-based immunotherapies. Divided into eighteen cohesive chapters, this book provides an in-depth and detailed look into cellular-based immunotherapies including CAR-T, TCR-T, TIL, Viral CTLs, NK cells in addition to T/NK cell engagers, focusing on their historical perspectives, biology, development and manufacturing, toxicities and more. Edited by two leading experts on gene and cellular immunotherapy, the book will feature chapters written by a diverse collection of recognized and up-and-coming experts and researchers in the field, providing oncologists, immunologists, researchers and clinical and basic science trainees with a bench to bedside view of the latest developments in the field.
650 2 4 $a Medical Microbiology. $3 668401
650 1 4 $a Biomedical Research. $3 643481
650 0 $a Pharmacology. $3 583819
650 0 $a Medical microbiology. $3 583124
650 0 $a Biology—Research. $3 1365799
650 0 $a Medicine—Research. $3 1365798
700 1 $a DiPersio, John F. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1399676
700 1 $a Ghobadi, Armin. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1399675
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030878481
776 0 8 $i Printed edition: $z 9783030878504
776 0 8 $i Printed edition: $z 9783030878511
830 0 $a Cancer Drug Discovery and Development, $x 2196-9906 $3 1253870
856 4 0 $u https://doi.org/10.1007/978-3-030-87849-8
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)